ArticleJAMA internal medicine2019

Communicating, and Justifying, Nonefficacy Benefits for New Drugs Approved on the Basis of Noninferiority Trials.

Joseph S Ross et al.PubMed ↗Publisher ↗

No numbers read from the abstract.